Neonmind Biosciences Inc (OP: NMDBF )

N/A UNCHANGED
Last Price Updated: 10:22 AM EST, Dec 14, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open -
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.0076
Today's Range N/A - N/A
52wk Range N/A - N/A
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
World Class Leaders In Psychedelics Form Benzinga's Psychedelic Advisory Council—Get To Know Them
The Benzinga Psychedelics Advisory Council was introduced in March of 2022 with the sustained goal of better informing investors and general audience about the psychedelics financial and business... 
Via Benzinga
Psyched: Big Pharma's Sanofi Enters Psychedelics Space, DNA From 80 Psilocybe Mushrooms Published Online, Maine Psychedelics Bill Shelved
Benzinga’s first-ever Psychedelics Capital Conference was a colossal success. Over 600 investors, policymakers, industry executives and thought leaders gathered at the Fontainebleau Hotel in Miami... 
Via Benzinga

Performance

More News

Read More
NeonMind To Improve Patient Care And Data Management With Thrive Health's Digital Healthcare Platform
Via Benzinga
NeonMind To Launch 10 Mental Health Clinics In Canada, How Will Patients Benefit?
Via Benzinga
NeonMind Announces Plan to Launch 10 Clinics for Innovative Treatments as Mental Health Crisis Grows
From NeonMind Biosciences Inc.
Via AccessWire
Psyched: Third Michigan City Decriminalizes Psychedelics, MindMed Reports $133M Cash Position, Real Brands To Enter The Space
Via Benzinga
NeonMind Files Provisional Patent Application For Psilocybin Induced Weight Loss
Via Benzinga
Psyched: Albert Labs Goes Public, Ex-Moderna Executive Joins MAPS, Novamind and Usona Join For Phase 2 Psilocybin Trial
Via Benzinga
NeonMind Completes Pre-IND Consultation With FDA And Strengthens Medical Services Division
Via Benzinga
Psyched: First Australian Psych Company On Nasdaq, Utah's Psychedelics Bill, LSD Vs. Psilocybin Study Unprecedented Results
Via Benzinga
NeonMind Teams Up With BioScript Solutions To Expand Its Clinic Network For Interventional Psychiatry Treatments
Via Benzinga
Cannabis Movers & Shakers: MedMen, Organigram, NeonMind, Green Check Verified
Via Benzinga
NeonMind Appoints Dr. Dinesh Bhayana As Site Medical Director Of Its First Mental Health Clinic
Via Benzinga
NeonMind To Open Its First Specialty Mental Health Clinic In Ontario, More To Come
Via Benzinga
Benzinga's Unprecedented Psychedelics Investing Conference Lands In Miami On April 19th
Via Benzinga
NeonMind to Present at H.C. Wainwright 2nd Annual Psychedelics Virtual Conference
From NeonMind Biosciences Inc.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
NeonMind Announces Successful Completion of Pre-IND Consultation with FDA on Clinical Path for Obesity Drug Candidate NEO-001
From NeonMind Biosciences Inc.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property Product Safety
NeonMind to Participate in Panel Discussion at Lift & Co. Expo's Psychedelics Business Summit on November 19, 2021
From NeonMind Biosciences Inc.
Via AccessWire
Topics Cannabis Intellectual Property
Exposures Cannabis Intellectual Property
NeonMind and SRx Health Solutions Announce Strategic Alliance to Establish Specialty Mental Health Clinics for Interventional Psychiatry Treatments
From NeonMind Biosciences Inc.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
NeonMind Biosciences Named as a Top Industry Innovator in Inaugural Issue of Psychedelia Magazine
From NeonMind Biosciences Inc.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
NeonMind Advances Strategy for Specialty Clinic Launch
From NeonMind Biosciences Inc.
Via AccessWire
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Psyched: The 50 Publicly-listed Psychedelics Companies, Atai's New Subsidiary, PharmaTher Gets New Orphan Drug Designation
Via Benzinga
NeonMind Strengthens its Specialty Clinics Advisory Board with Appointment of Mood Disorders and Ketamine Expert Dr. Gustavo Vazquez, MD, PhD.
From NeonMind Biosciences Inc.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
There Are Now 50 Psychedelics Companies Listed In The U.S. - Here They Are
Via Benzinga
NeonMind Appoints Ketamine and Neurostimulation Expert Dr. Roumen Milev, MD, PhD to Specialty Clinic Advisory Board
From NeonMind Biosciences Inc.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.